Home  »  Stock Ideas   »  PDS Biotechnology Corporation (PDSB) revealed pret...

PDS Biotechnology Corporation (PDSB) revealed pretty balanced Earnings results as it emphasizes cost-cutting measures

Thursday, November 12, 2020, A company in the biotech sector PDS Biotechnology Corporation (Nasdaq: PDSB), publicized its quarterly results for the period ended 30 September 2020 and provided a business update.

Net losses were almost $3.9 million for the third quarter of 2020, or $0.23 per basic share and diluted share, compared to a net loss of approximately $5.8 million for the third quarter of 2019, or $1.10 per basic share and diluted share.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


For the previous quarter, R&D costs reached about $2.1 million, in contrast to $1.8 million at the same time in 2019, an improvement of 12 percent. The rise was mainly due to an increase in tech addition to operations of $0.1 million and clinical trials of $0.3 million, counterbalanced by a decline in professional fees of $0.1 million and regulatory expenses of $0.1 million.

General and administrative expenses were roughly $1.8 million for the period compared to $3.0 million years over year, which was a decline of 40 percent. The drop was largely due to a $0.2 million cut down in salaries and benefits, $0.1 million in expenditures for services and offices, $0.3 million in insurance costs, $0.6 million in professional fees, and $0.1 million in legal fees, offset by a rise in permits, taxes, and fees of $0.1 million.

Expenses related to the operation were almost $3.9 million for the third quarter, in comparison with total operating expenses of $5.8 million during the same quarter year before, which was a 33 percent decline.

The clinical-stage immunotherapy company that develops novel cancer therapies and medications for transferrable diseases based on the company’s patented activating technology Versamune T-cell. Its cash balance was recorded $33.5 million as of September 30, 2020.

PDS Biotechnology Corporation (Nasdaq: PDSB) shares were trading 1.94% away from the 20-day Simple Moving Average. Its last month’s performance was recorded -9.73% in contrast with the 6 months performance of 151.38%.

Leave a Comment

Your email address will not be published. Required fields are marked *